MGC 028
Alternative Names: MGC-028Latest Information Update: 02 Apr 2025
At a glance
- Originator MacroGenics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Mar 2025 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT06723236),
- 09 Dec 2024 MacroGenics plans to initiates a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/unresectable, Second-line therapy or greater) in unknown location (IV) (NCT06723236)
- 05 Nov 2024 MacroGenics submits an IND application to the US FDA for Solid tumours in October 2024